← All trials
NCT05296733
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 27, 2022
- Primary completion
- Aug 24, 2023
- Completion date
- Aug 24, 2023
- First posted
- Mar 25, 2022
- Last posted
- Dec 14, 2022
- Enrollment
- 80
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Boehringer IngelheimLead sponsor
- Zealand PharmaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.